British Gynaecological Cancer Society/British Association of Gynaecological Pathology consensus for germline and tumor testing for BRCA1/2 variants in ovarian cancer in the United Kingdom

Research output: Contribution to journalReview articlepeer-review


  • Ranjit Manchanda
  • Charlie Gourley
  • Angela George
  • Andrew Wallace
  • Janos Balega
  • Sarah Williams
  • Yvonne Wallis
  • Richard Edmondson
  • Shibani Nicum
  • Jonathan Frost
  • Ayoma Attygalle
  • Christina Fotopoulou
  • Rebecca Bowen
  • Dani Bell
  • Ketankumar Gajjar
  • Bruce Ramsay
  • Nicholas J Wood
  • Sadaf Ghaem-Maghami
  • Tracie Miles
  • Raji Ganesan

Colleges, School and Institutes

External organisations

  • Barts Cancer Institute
  • University of Edinburgh, The
  • The Royal Marsden Hospital NHS Foundation Trust
  • St Mary's Hospital London
  • Birmingham Women's and Children's Hospital NHS Foundation Trust
  • Manchester University Hospitals NHS Foundation Trust
  • Oxford University Hospitals NHS Foundation Trust
  • Royal United Hospitals Bath NHS Foundation Trust, 1556, Bath, United Kingdom of Great Britain and Northern Ireland
  • University Hospital Zürich
  • Nottingham University Hospitals NHS Trust
  • Peterborough City Hospital
  • Royal Preston Hospital Lancashire Teaching Hospitals NHS Foundation Trust
  • Imperial College London
  • Royal United Hospitals Bath
  • University Hospitals Birmingham NHS Foundation Trust
  • Gynaecologic Oncology, Imperial Hospitals NHS trust, London, UK
  • Department of Gynaecological Oncology


The British Gynecological Cancer Society and the British Association of Gynecological Pathologists established a multidisciplinary consensus group comprising experts in surgical gynecological oncology, medical oncology, genetics, and laboratory science, and clinical nurse specialists to identify the optimal pathways to BRCA germline and tumor testing in patients with ovarian cancer in routine clinical practice. In particular, the group explored models of consent, quality standards identified at pathology laboratories, and experience and data from pioneering cancer centers. The group liaised with representatives from ovarian cancer charities to also identify patient perspectives that would be important to implementation. Recommendations from these consensus group deliberations are presented in this manuscript.


Original languageEnglish
Pages (from-to)272-278
Number of pages7
JournalInternational Journal of Gynecological Cancer
Issue number2
Publication statusPublished - 1 Feb 2021


  • BRCA1 protein, BRCA2 protein, fallopian tube neoplasms, ovarian neoplasms

ASJC Scopus subject areas